Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.
about
Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodiesParabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer CellsExpression and function of heregulin-alpha and its receptors in the mouse mammary gland.An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.Genome-based risk prediction for early stage breast cancer.Novel pharmacological approaches in the treatment of breast cancer.The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines.Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities.Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.Effect of HER2 status on distant recurrence in early stage breast cancerGeneralized principles of stochasticity can be used to control dynamic heterogeneityPhosphorylated-p38 mitogen-activated protein kinase expression is associated with clinical factors in invasive breast cancer.Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort.Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.Roles of p38α mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer.Clinical utility of gene-expression signatures in early stage breast cancer.CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.Nuclear HER3 is associated with favorable overall survival in uveal melanoma.Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.
P2860
Q27683825-DD9492E3-C4AF-4CA4-B2B8-659B4BD13210Q29109837-A874066C-EE32-423C-B7CB-67C876371CFCQ33686043-28DF423F-8E40-43C4-888B-E1D380BAAE9EQ33777427-D06C3871-4F46-40F1-A1F3-C604031DED2AQ34359289-80EC57A4-6101-4726-893A-75AB93B6A693Q35143980-5FD13716-F72C-415E-B412-A024A4E28AE1Q35357793-87157748-6BF7-4D9E-83F8-45220AAAA73FQ35638363-AE559332-AB78-43ED-A9EB-F2AA7E7F28DDQ36070998-D892FA91-B99D-464E-A124-8BD261379425Q36530791-3642BD89-8832-4182-969E-D9E1F783B65FQ36745875-53225253-CA15-4308-9005-354C07BE2B15Q37056598-4DC1714F-03C7-4FF1-B5DB-DF454B2D2E45Q37373606-1C9F4C71-1959-4A74-8176-9F9FA8E1BB53Q37564335-EE22E60F-8F79-4295-A917-959B0C65F172Q38366515-E742D0E0-D494-4D12-BDFC-EDE21AC6E38FQ38754717-0654152B-BBFF-41DA-B6B1-22B6834B7227Q38875316-9BF83BFB-8B70-4196-B3B8-69A64BC659C2Q39560158-5AF642B0-65D6-43DE-BACA-04D468CEF403Q41881505-622E0557-151C-4AA8-84A8-4AAC734CDA81Q47158524-54E45C81-C4DD-4249-A156-5B65A6711080Q51099066-FCDDC71F-4B9F-47A7-ABB1-9EA187F8457D
P2860
Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Expression of erbB/HER recepto ...... titative immunohistochemistry.
@ast
Expression of erbB/HER recepto ...... titative immunohistochemistry.
@en
type
label
Expression of erbB/HER recepto ...... titative immunohistochemistry.
@ast
Expression of erbB/HER recepto ...... titative immunohistochemistry.
@en
prefLabel
Expression of erbB/HER recepto ...... titative immunohistochemistry.
@ast
Expression of erbB/HER recepto ...... titative immunohistochemistry.
@en
P2093
P356
P1476
Expression of erbB/HER recepto ...... titative immunohistochemistry.
@en
P2093
Hortobagyi GN
P2860
P2888
P304
P356
10.1007/BF03032345
P577
2001-01-01T00:00:00Z